DRTX / Durata Therapeutics Inc - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

DRTX / Durata Therapeutics Inc 15-12B - - 15-12B

15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35599 Durata Therapeutics, Inc. (Exact name of registrant as spec

EX-99

Exhibit 99 Form 4 Joint Filer Information Names of Joint Filers: Canaan VIII L.P. Canaan Partners VIII LLC Canaan Management, Inc. Address of Joint Filers: c/o Canaan Partners 285 Riverside Avenue, Suite 250 Westport, CT 06880 Designated Filer: Canaan VIII L.P. Issuer and Ticker Symbol: Durata Therapeutics, Inc. [DRTX] Date of Event: November 17, 2014 Signatures of Joint Filers: Canaan VIII L.P. B

DRTX / Durata Therapeutics Inc / New Leaf Ventures II, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 26658A 10 7 (CUSIP Number) Craig L. Slutzkin New Leaf Venture Management II, L.L.C., Times Square Tower 7 Times Square, Suite 3502

MRH / Montpelier Re Holdings Ltd / Canaan VIII LP - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* DURATA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 26658A 107 (CUSIP Number) CANAAN VIII L.P. c/o CAN

DRTX / Durata Therapeutics Inc / AISLING CAPITAL III LP - AMENDMENT NO. 3 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 26658A 10 7 (CUSIP Number) Lloyd Appe

DRTX / Durata Therapeutics Inc SC 14D9/A - - SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 DURATA THERAPEUTICS, INC. (Name of Subject Company) DURATA THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 26

DRTX / Durata Therapeutics Inc POS AM - - POS AM

POS AM As filed with the Securities and Exchange Commission on November 17, 2014 Registration No.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commis

DRTX / Durata Therapeutics Inc S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on November 17, 2014 Registration No.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION DURATA THERAPEUTICS, INC.

EX-3.1 2 d822392dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DURATA THERAPEUTICS, INC. FIRST: The name of the Corporation is Durata Therapeutics, Inc. (the “Corporation”). SECOND: The Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, State of Delaware 19801.

DRTX / Durata Therapeutics Inc S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on November 17, 2014 Registration No.

DRTX / Durata Therapeutics Inc S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on November 17, 2014 Registration No.

Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer

EX-99.(a)(1)(J) Exhibit (a)(1)(J) NEWS RELEASE CONTACTS: Investors: Lisa DeFrancesco (862) 261-7152 Media: Charlie Mayr (862) 261-8030 David Belian (862) 261-8141 Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer DUBLIN, IRELAND – November 17, 2014 – Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of

DURATA THERAPEUTICS, INC. AMENDED AND RESTATED BYLAWS As Adopted on November 17, 2014 TABLE OF CONTENTS ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1.01 Annual Meetings 1 Section 1.02 Special Meetings 1 Section 1.03 Participation in Meetings by Remo

EX-3.2 Exhibit 3.2 DURATA THERAPEUTICS, INC. AMENDED AND RESTATED BYLAWS As Adopted on November 17, 2014 TABLE OF CONTENTS ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1.01 Annual Meetings 1 Section 1.02 Special Meetings 1 Section 1.03 Participation in Meetings by Remote Communication 1 Section 1.04 Notice of Meetings; Waiver of Notice 1 Section 1.05 Proxies 2 Section 1.06 Voting Lists 2 Section 1

AGN / Allergan plc SC TO-T/A - - SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) DURATA THERAPEUTICS, INC. (Name of Subject Company) DELAWARE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ACTAVIS W.C. HOLDING INC. (Offeror) An Indirect Wholly Owned Su

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2014 (November 9, 2014) DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction o

Durata Therapeutics 10-Q (Quarterly Report)

10-Q 1 d773629d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SECOND AMENDMENT TO SUPPLY AGREEMENT

EX-10.4 Exhibit 10.4 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SECOND AMENDMENT TO SUPPLY AGREEMENT THIS AMENDMENT is entered into this 22nd day of August, 2014, by and between Gnosis Bioresearch srl., a subsidiary fully owned company by GNOSIS SPA organized under the laws of Italy whose head office is locate

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

EX-10.5 5 d773629dex105.htm EX-10.5 Exhibit 10.5 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “Amendment”) to that certain Employment Agreement by and between Durata Therapeutics, Inc. and John Shannon (“Executive”), effective as of June 20, 2012 (the “Agreement”), is made and entered into July 29, 2014 (the “Amendment Effective Date”). Certain capitalized term shall have the

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SUPPLY AGREEMENT

EX-10.2 Exhibit 10.2 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SUPPLY AGREEMENT This Supply Agreement (?Agreement?), effective as of July 29, 2014 (the ?Effective Date?), is made by and between Durata Therapeutics International B.V., a company registered in the Netherlands with offices at Spaces Zuidas II, Ba

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT

EX-10.3 Exhibit 10.3 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT This License Agreement (?Agreement?), effective as of July 29, 2014 (the ?Effective Date?), is made by and between Durata Therapeutics International B.V. (?B.V.?), a company registered in the Netherlands with offices at Spaces Zu

DRTX / Durata Therapeutics Inc SC 14D9/A - - SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 DURATA THERAPEUTICS, INC. (Name of Subject Company) DURATA THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 26

Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Durata

EX-99.(A)(1)(I) 2 d812425dex99a1i.htm EX-99.(A)(1)(I) Exhibit (a)(1)(I) NEWS RELEASE CONTACTS: Actavis: Investors: Lisa DeFrancesco (862) 261-7152 Media: Charlie Mayr (862) 261-8030 David Belian (862) 261-8141 Durata: Allison Wey (312) 219-7017 Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Durata DUBLIN, IRELAND and CHICAGO, IL – October 31, 2014 –

AGN / Allergan plc SC TO-T/A - - AMENDMENT NO. 2 TO SCHEDULE TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DURATA THERAPEUTICS, INC. (Name of Subject Company) DELAWARE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ACTAVIS W.C. HOLDING INC. (Offeror) An Indirect Wholly Owned Su

DRTX / Durata Therapeutics Inc SC 14D9/A - - SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 DURATA THERAPEUTICS, INC. (Name of Subject Company) DURATA THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 26

AGN / Allergan plc SC TO-T/A - - AMENDMENT NO.1 TO SCHEDULE TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DURATA THERAPEUTICS, INC. (Name of Subject Company) DELAWARE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ACTAVIS W.C. HOLDING INC. (Offeror) An Indirect Wholly Owned Su

DRTX / Durata Therapeutics Inc CORRESP - -

SEC Letter October 24, 2014 Brian A. Johnson +1 (212) 937-7206 (t) +1 (212) 230-8888 (f) [email protected] Jay E. Bothwick VIA EDGAR SUBMISSION +1 (617) 526-6526 (t) +1 (617) 526-5000 (f) [email protected] Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 6010 Washington, DC 20549-6010 Attention: Daniel F. Duchovny Re: Durata Therape

DRTX / Durata Therapeutics Inc SC 14D9/A - - SCHEDULE 14D-9/A

Schedule 14D-9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 DURATA THERAPEUTICS, INC. (Name of Subject Company) DURATA THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securit

LETTER OF TRANSMITTAL To Tender Shares of Common Stock DURATA THERAPEUTICS, INC. a Delaware corporation $23.00 per share plus one non-transferable contractual contingent value right for each share, which represents the right to receive contingent pay

EX-(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of DURATA THERAPEUTICS, INC.

October 17, 2014

EX-99.(A)(9) 2 d805914dex99a9.htm EX-99.(A)(9) Exhibit (a)(9) October 17, 2014 Dear Stockholder: I am pleased to inform you that, on October 5, 2014, Durata Therapeutics, Inc. (“Durata”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Actavis W.C. Holding Inc. (“Parent”) and Delaware Merger Sub, Inc. (“Purchaser”), a wholly owned subsidiary of Parent and an indirect whol

DRTX / Durata Therapeutics Inc SC 14D9 - - SC 14D9

SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Offer To Purchase For Cash All Outstanding Shares of Common Stock DURATA THERAPEUTICS, INC. a Delaware corporation $23.00 per share plus one non-transferable contractual contingent value right for each share, which represents the right to receive con

EX-(a)(1)(D) Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of DURATA THERAPEUTICS, INC.

NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock DURATA THERAPEUTICS, INC. a Delaware corporation $23.00 per share plus one non-transferable contractual contingent value right for each share, which represents the right to receive co

EX-(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of DURATA THERAPEUTICS, INC.

Offer to Purchase for Cash All Outstanding Shares of Common Stock DURATA THERAPEUTICS, INC. $23.00 per share plus one non-transferable contractual contingent value right for each share, which represents the right to receive contingent payments of up

EX-(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of DURATA THERAPEUTICS, INC.

Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock DURATA THERAPEUTICS, INC. a Delaware corporation $23.00 per share plus one non-transferable contractual contingent value right for each share, which represents the right to r

EX-(a)(1)(H) Exhibit (a)(1)(H) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).

AGN / Allergan plc SC TO-T - - SCHEDULE TO

Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURATA THERAPEUTICS, INC. (Name of Subject Company) DELAWARE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ACTAVIS W.C. HOLDING INC. (Offeror) An Indirect Wholly Owned Subsidia

Offer To Purchase For Cash All Outstanding Shares of Common Stock DURATA THERAPEUTICS, INC. a Delaware corporation $23.00 per share plus one non-transferable contractual contingent value right for each share, which represents the right to receive con

EX-(a)(1)(E) Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of DURATA THERAPEUTICS, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2014 (October 5, 2014) DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of I

AGN / Allergan plc SC TO-C - - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 8, 2014 (October 5, 2014) ACTAVIS plc (Exact name of registrant as specified in its charter) Ireland 000-55075 98-1114402 (State or other jurisdiction of incorporatio

Form of CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENT

Exhibit 99.1 Form of CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ ], 2014 (this “Agreement”), is entered into by and between Actavis W.C. Holding Inc., a Delaware corporation (“Parent”), and [ ], a [ ], as Rights Agent. PREAMBLE WHEREAS, Durata Therapeutics, Inc., a Delaware corporation (the “Company”), Parent and Delaware Merger Sub, Inc.,

TENDER AND SUPPORT AGREEMENT

EX-99.2 4 d802754dex992.htm EX-99.2 Exhibit 99.2 EXECUTION COPY TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 5, 2014, is entered into by and among Actavis W.C. Holding Inc., a Delaware corporation (“Parent”), Delaware Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Merger Sub”), and each of the pers

AGREEMENT AND PLAN OF MERGER by and among ACTAVIS W.C. HOLDING INC., DELAWARE MERGER SUB, INC. DURATA THERAPEUTICS, INC. Dated as of October 5, 2014 TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.01 The Offer 2 Section 1.02 Company Action 4 ART

EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among ACTAVIS W.C. HOLDING INC., DELAWARE MERGER SUB, INC. and DURATA THERAPEUTICS, INC. Dated as of October 5, 2014 TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.01 The Offer 2 Section 1.02 Company Action 4 ARTICLE II THE MERGER Section 2.01 The Merger 6 Section 2.02 Consummation of the Merger 6 Section 2.03 Effects o

Date: October 6, 2014 To: All Employees of Our Global Company From: Brent Saunders, CEO & President Re: Actavis Announces Acquisition of Durata Therapeutics; Expands Infectious Disease Product Portfolio

EX-99.2 Exhibit 99.2 Date: October 6, 2014 To: All Employees of Our Global Company From: Brent Saunders, CEO & President Re: Actavis Announces Acquisition of Durata Therapeutics; Expands Infectious Disease Product Portfolio I am pleased to announce that Actavis has reached an agreement to acquire Durata Therapeutics (NASDAQ: DRTX), an innovative pharmaceutical company headquartered in Chicago, IL,

Actavis to Acquire Durata Therapeutics, Inc. – Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings – – Enhances Actavis’ Long-term Growth Profile 2015+ – – Experienced Development and Commercial Team B

EX-99.2 Exhibit 99.2 NEWS RELEASE CONTACTS: Actavis: Investors: Lisa DeFrancesco (862) 261-7152 Media: Charlie Mayr (862) 261-8030 David Belian (862) 261-8141 Durata: Allison Wey (312) 219-7017 Actavis to Acquire Durata Therapeutics, Inc. – Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings – – Enhances Actavis’ Long-term Growth Profile 2015+ – – E

TENDER AND SUPPORT AGREEMENT

EX-99.1 Exhibit 99.1 EXECUTION COPY TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 5, 2014, is entered into by and among Actavis W.C. Holding Inc., a Delaware corporation (“Parent”), Delaware Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Merger Sub”), and each of the persons set forth on Schedule A

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commissi

AGN / Allergan plc SC TO-C - - FORM 8-K

SC TO-C 1 d800421d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2014 (October 5, 2014) ACTAVIS plc (Exact name of registrant as specified in its charter) Ireland 000-55075 98-1114402 (State or other jur

DRTX / Durata Therapeutics Inc SC14D9C - - SCHEDULE 14D-9C

SCHEDULE 14D-9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DURATA THERAPEUTICS, INC. (Name of Subject Company) DURATA THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 26658A107 (CUSIP Number of C

Actavis to Acquire Durata Therapeutics, Inc. – Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings – – Enhances Actavis’ Long-term Growth Profile 2015+ – – Experienced Development and Commercial Team B

EX-99.1 2 d800421dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: Actavis: Investors: Lisa DeFrancesco (862) 261-7152 Media: Charlie Mayr (862) 261-8030 David Belian (862) 261-8141 Durata: Allison Wey (312) 219-7017 Actavis to Acquire Durata Therapeutics, Inc. – Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings – – Enhances Actavis’ Long-ter

AGREEMENT AND PLAN OF MERGER by and among ACTAVIS W.C. HOLDING INC., DELAWARE MERGER SUB, INC. DURATA THERAPEUTICS, INC. Dated as of October 5, 2014 TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.01 The Offer 2 Section 1.02 Company Action 4 ART

EX-2.1 2 d800599dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among ACTAVIS W.C. HOLDING INC., DELAWARE MERGER SUB, INC. and DURATA THERAPEUTICS, INC. Dated as of October 5, 2014 TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.01 The Offer 2 Section 1.02 Company Action 4 ARTICLE II THE MERGER Section 2.01 The Merger 6 Section 2.02 Consummation of the Merge

DRTX / Durata Therapeutics Inc S-8 - - S-8

S-8 As filed with the Securities and Exchange Commission on September 30, 2014 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commissi

Entry into a Material Definitive Agreement

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Com

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Com

Durata Therapeutics FORM 10-Q (Quarterly Report)

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Comm

OFFICE LEASE PIEDMONT 500 WEST MONROE FEE LLC, a Delaware limited liability company, DURATA THERAPEUTICS, INC. a Delaware corporation TABLE OF CONTENTS Page No. ARTICLE 1 Premises and Term 1 ARTICLE 2 Base Rent 2 ARTICLE 3 Additional Rent 3 ARTICLE 4

EX-10.2 3 d726595dex102.htm EX-10.2 Exhibit 10.2 OFFICE LEASE Between PIEDMONT 500 WEST MONROE FEE LLC, a Delaware limited liability company, and DURATA THERAPEUTICS, INC. a Delaware corporation TABLE OF CONTENTS Page No. ARTICLE 1 Premises and Term 1 ARTICLE 2 Base Rent 2 ARTICLE 3 Additional Rent 3 ARTICLE 4 Use and Rules 7 ARTICLE 5 Services and Utilities 7 ARTICLE 6 Alterations and Liens 9 ART

AMENDMENT NUMBER ONE TO EMPLOYMENT AGREEMENT BETWEEN DURATA THERAPEUTICS, INC. AND MICHAEL DUNNE

EX-10.1 Exhibit 10.1 AMENDMENT NUMBER ONE TO EMPLOYMENT AGREEMENT BETWEEN DURATA THERAPEUTICS, INC. AND MICHAEL DUNNE This AMENDMENT NUMBER ONE (the ?Amendment?) to the Employment Agreement dated June 10, 2012 (the ?Agreement?) is made as of May 1, 2014 between Durata Therapeutics, Inc. (the ?Company?), and Michael Dunne (?Employee?). WHEREAS, the Company and the Employee entered into the Agreemen

DURATA THERAPEUTICS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 DURATA THERAPEUTICS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS CHICAGO, IL, August 7, 2014 (GLOBE NEWSWIRE) – Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced financial results for the quarter ended June 30, 2014. “This was a very busy and exciting quarter for Durata during which we achieved several major milestones: the approval of DALVANCETM in late May; our data

Entry into a Material Definitive Agreement

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2014 Durata Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (C

Entry into a Material Definitive Agreement - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2014 Durata Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Co

DRTX / Durata Therapeutics Inc / AISLING CAPITAL III LP - AMENDMENT NO. 2 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 26658A 10 7 (CUSIP Number) Lloyd Appe

Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2014 Durata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commiss

Durata Therapeutics FORM 10-Q (Quarterly Report)

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commission F

DURATA THERAPEUTICS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 DURATA THERAPEUTICS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS CHICAGO, IL, May 8, 2014 (GLOBE NEWSWIRE) – Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced financial results for the quarter ended March 31, 2014. “The first quarter of 2014 ended on a high note with the unanimous recommendation by the FDA’s Anti-Infective Drugs Advisory Committee for the approval of Da

-

Acceleration Request DURATA THERAPEUTICS, INC. 200 S. WACKER DRIVE, SUITE 2550 CHICAGO, ILLINOIS 60606 April 22, 2014 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Durata Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-194866 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgate

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

DRTX / Durata Therapeutics Inc / SOFINNOVA VENTURE PARTNERS VII L P - SC 13D/A Activist Investment

CUSIP NO. 26658A107 13D Page 1 of 14 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 26658A107 (CUSIP

Calculation of Consolidated Ratios of Earnings to Fixed Charges For the year ended December 31, For the period ended December 31, 2009 2013 2012 2011 2010 Fixed Charges: Interest expense on indebtedness 2,226 — — — — Portion of rent expense represent

EX-12.1 Exhibit 12.1 Calculation of Consolidated Ratios of Earnings to Fixed Charges For the year ended December 31, For the period ended December 31, 2009 2013 2012 2011 2010 Fixed Charges: Interest expense on indebtedness 2,226 — — — — Portion of rent expense representative of interest (a) 222 167 75 15 — Total Fixed Charges 2,448 167 75 15 — Earnings (loss): Net income (loss) before provision f

Form of Subordinated Note (FACE OF SECURITY)

EX-4.5 5 d699016dex45.htm EX-4.5 Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO T

Form of Senior Note (FACE OF SECURITY)

EX-4.4 Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Durata Therapeutics, Inc. Dated as of Subordinated Debt Securities Cross-Reference Table(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inappl

EX-4.3 Exhibit 4.3 Durata Therapeutics, Inc. and Trustee Indenture Dated as of Subordinated Debt Securities Cross-Reference Table(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a)

- S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2014 Registration No.

Durata Therapeutics, Inc. Dated as of Senior Debt Securities Cross-Reference Table(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable

EX-4.2 Exhibit 4.2 Durata Therapeutics, Inc. and Trustee Indenture Dated as of Senior Debt Securities Cross-Reference Table(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 3

DRTX / Durata Therapeutics Inc / AISLING CAPITAL III LP - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 26658A 10 7 (CUSIP Number) Lloyd Appe

- FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on March 21, 2014 Registration No.

DURATA THERAPEUTICS, INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2013 FINANCIAL RESULTS

EX-99.1 2 d691746dex991.htm EX-99.1 Exhibit 99.1 DURATA THERAPEUTICS, INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2013 FINANCIAL RESULTS CHICAGO, IL, March 14, 2014 (GLOBE NEWSWIRE) – Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced its fourth quarter and full year 2013 financial results. “2013 was a year of incredible achievement for Durata, including data presentations of our DISCOVER prog

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2014 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commission Fi

DRTX / Durata Therapeutics Inc / Wellington Management Group LLP - DISCLOSURE DOCUMENT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Durata Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 26658A107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

DRTX / Durata Therapeutics Inc / Quaker BioVentures II LP - QUAKER BIOVENTURES II, L.P. FORM SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information To Be Included In Statements Filed Pursuant To § 240.13d-1(b), (c), and (d) and Amendments Thereto Filed Pursuant To § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Cla

DRTX / Durata Therapeutics Inc / ORBIMED ADVISORS LLC - SCHEDULE 13G HOLDINGS REPORT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Durata Therapeutics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2013 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commis

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2013 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Co

DURATA THERAPEUTICS, INC. REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 DURATA THERAPEUTICS, INC. REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS CHICAGO, IL, November 6, 2013 – Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced financial results for the quarter ended September 30, 2013. Financial results for the quarter ended September 30, 2013 As of September 30, 2013, we had cash and cash equivalents plus short-term investments of $66.6 mill

DURATA THERAPEUTICS, INC. REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Timing of NDA and MAA Submissions Remain on Track

EX-99.1 Exhibit 99.1 DURATA THERAPEUTICS, INC. REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Timing of NDA and MAA Submissions Remain on Track CHICAGO, IL, August 7, 2013 – Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced financial results for the quarter ended June 30, 2013. Q2 2013 Highlights and Recent Events Accomplishments include the following: • Completed an equity offering in April

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2013 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Comm

Submission of Matters to a Vote of Security Holders - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2013 Durata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Co

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2013 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commission F

DURATA THERAPEUTICS, INC. REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS -Raised $54 million in recent equity offering-

EX-99.1 Exhibit 99.1 DURATA THERAPEUTICS, INC. REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS -Raised $54 million in recent equity offering- CHICAGO, IL, May 9, 2013 – Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced financial results for the quarter ended March 31, 2013. Financial results for the quarter ended March 31, 2013 As of March 31, 2013, we had cash and cash equivalents plus short-

DRTX / Durata Therapeutics Inc / Vivo Ventures VI, LLC - SCHEDULE 13G FOR DURATA THERAPEUTICS, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Rule 13d-102) (Amendment No.

7,150,000 Shares Common Stock

424B4 1 d511012d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) File No. 333-187630 P R O S P E C T U S 7,150,000 Shares Common Stock We are selling 7,150,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol “DRTX.” The last reported sale price of our common stock on April 11, 2013 was $7.28 per share. We are an “emerging growth

DURATA THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT

EX-1.1 Exhibit 1.1 DURATA THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [•], 2013 DURATA THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT [•], 2013 Merrill Lynch, Pierce, Fenner & Smith Incorporated Credit Suisse Securities (USA) LLC Jefferies LLC as Representatives of the several Underwriters c/o M

- S-1/A

S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 9, 2013 Registration No.

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

LOAN AND SECURITY AGREEMENT

EX-10.19 Exhibit 10.19 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of March 5, 2013 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule

WARRANT TO PURCHASE STOCK Company: DURATA THERAPEUTICS, INC., a Delaware corporation Number of Shares: [$295,000/WARRANT PRICE; NOTE: TOTAL WARRANT COVERAGE EQUAL TO 2.95% OF FUNDED LOAN AMOUNT] Type/Series of Stock: Common Stock, par value $0.01 per

EX-10.20 Exhibit 10.20 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR, IN THE OPINI

SUBORDINATION AGREEMENT

EX-10.23 Exhibit 10.23 SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of March 5, 2013, by and among each of the parties listed as a creditor on a signature page hereto (each, a “Creditor”), and OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314, in its capacity as Collateral Age

Registration Statement - S-1

S-1 Table of Contents As filed with the Securities and Exchange Commission on March 29, 2013 Registration No.

SECURITY AGREEMENT

EX-10.21 Exhibit 10.21 SECURITY AGREEMENT This Security Agreement (this “Agreement”) is entered into as of March 5, 2013, by and between OXFORD FINANCE LLC (“Oxford”; and, in its capacity as collateral agent for the Lenders under the Loan Agreement (as defined below), “Collateral Agent”) and each of the undersigned pledgors (each a “Pledgor” and collectively, the “Pledgors”). RECITALS DURATA THERA

UNCONDITIONAL GUARANTY

EX-10.22 Exhibit 10.22 UNCONDITIONAL GUARANTY This continuing Unconditional Guaranty (“Guaranty”) is entered into as of March 5, 2013, by each of the undersigned (each a “Guarantor” and collectively “Guarantors”), in favor of OXFORD FINANCE LLC (“Oxford”; and, in its capacity as collateral agent for the Lenders under the Loan Agreement (as defined below), “Collateral Agent”). RECITALS A. Concurren

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2013 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commission

DURATA THERAPEUTICS, INC. REPORTS FULL-YEAR 2012 FINANCIAL -Entered into a $20 million debt facility-

EX-99.1 Exhibit 99.1 DURATA THERAPEUTICS, INC. REPORTS FULL-YEAR 2012 FINANCIAL RESULTS -Entered into a $20 million debt facility- CHICAGO, IL, March 8, 2013 – Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced financial results for the year ended December 31, 2012. “2012 was a great year for Durata. We accomplished many things from a clinical, regulatory and organizational perspective that

DURATA THERAPEUTICS REPORTS THIRD QUARTER 2012 FINANCIAL AND CORPORATE RESULTS

Exhibit 99.1 DURATA THERAPEUTICS REPORTS THIRD QUARTER 2012 FINANCIAL AND CORPORATE RESULTS MORRISTOWN, NJ, November 9, 2012 – Durata Therapeutics (NASDAQ: DRTX) today announced financial and corporate results for the quarter ended September 30, 2012. “With the completion of patient enrollment in our two ongoing global Phase 3 clinical trials of dalbavancin, we remain on track to file a New Drug A

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2012 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Co

- FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on October 5, 2012 Registration No.

DURATA THERAPEUTICS, INC. REPORTS SECOND QUARTER 2012 FINANCIAL AND CORPORATE RESULTS

Press Release of Durata Therapeutics, Inc., dated September 4, 2012 Exhibit 99.1 DURATA THERAPEUTICS, INC. REPORTS SECOND QUARTER 2012 FINANCIAL AND CORPORATE RESULTS MORRISTOWN, NJ, September 4, 2012 – Durata Therapeutics, Inc. (NASDAQ: DRTX), a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses,

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2012 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (C

Entry into a Material Definitive Agreement - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2012 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Com

Entry into a Material Definitive Agreement - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2012 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Comm

DRTX / Durata Therapeutics Inc / Domain Partners VIII, L.P. - SCHEDULE 13D FOR DURATA THERAPEUTICS, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

DRTX / Durata Therapeutics Inc / New Leaf Ventures II, L.P. - SCHEDULE 13D Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 26658A 107 (CUSIP Number) Craig L. Slutzkin New Leaf Venture Management II, L.L.C., Times Square Tower 7 Times Square, Suite 350

DRTX / Durata Therapeutics Inc / SOFINNOVA VENTURE PARTNERS VII L P - SCHEDULE 13D Activist Investment

CUSIP NO. 26658A107 13D Page 1 of 14 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 26658A107 (CUSIP

DRTX / Durata Therapeutics Inc / Canaan VIII LP - SCHEDULE 13D Activist Investment

Schedule 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* DURATA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 26658A 107 (CUSIP Number) CANAAN VIII L.P. c/o

EX-99.1

Exhibit 99.1 Form 3 Joint Filer Information Names of Joint Filers: Canaan VIII L.P. Canaan Partners VIII LLC Canaan Management, Inc. Address of Joint Filers: c/o Canaan Partners 285 Riverside Avenue, Suite 250 Westport, CT 06880 Designated Filer: Canaan VIII L.P. Issuer and Ticker Symbol: Durata Therapeutics, Inc. [DRTX] Date of Event: July 24, 2012 Signatures of Joint Filers: Canaan VIII L.P. By:

DRTX / Durata Therapeutics Inc / Quaker BioVentures II LP - QUAKER BIOVENTURES II, L.P. FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information To Be Included In Statements Filed Pursuant To § 240.13d-1(b), (c), and (d) and Amendments Thereto Filed Pursuant To § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class

EX-99

Exhibit 99 Form 4 Joint Filer Information Names of Joint Filers: Canaan VIII L.P. Canaan Partners VIII LLC Canaan Management, Inc. Address of Joint Filers: c/o Canaan Partners 285 Riverside Avenue, Suite 250 Westport, CT 06880 Designated Filer: Canaan VIII L.P. Issuer and Ticker Symbol: Durata Therapeutics, Inc. [DRTX] Date of Event: July 24, 2012 Signatures of Joint Filers: Canaan VIII L.P. By: C

Exhibit 2:

EXHIBIT 2 3/21, 2012 Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse Securities (USA) LLC as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010-3629 Re: Proposed Public Offering by Durata Therapeutics, Inc.

Durata Therapeutics Adds Independent Director Lisa M. Giles to the Company’s Board

Press Release Exhibit 99.1 Durata Therapeutics Adds Independent Director Lisa M. Giles to the Company’s Board MORRISTOWN, N.J. — (BUSINESS WIRE) — July 27, 2012 — Durata Therapeutics (NASDAQ: DRTX) today announced that, as contemplated by the prospectus related to the company’s initial public offering, the company’s board of directors appointed a new independent director to the board to replace on

DRTX / Durata Therapeutics Inc / AISLING CAPITAL III LP - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Durata Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 26658A 10 7 (CUSIP Number) Lloyd Appel A

Exhibit 1:

EXHIBIT 1 JOINT FILING AGREEMENT Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit (the “Schedule 13D”), and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned.

Exhibit 3:

EXHIBIT 3 Purchase of Common Stock in the Initial Public Offering of Durata Therapeutics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2012 DURATA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35599 27-1247903 (State or Other Jurisdiction of Incorporation) (Commi

7,500,000 Shares Common Stock

Final Prospectus Table of Contents Filed Pursuant to Rule 424(b)(4) File No. 333-180280 P R O S P E C T U S 7,500,000 Shares Common Stock This is Durata Therapeutics, Inc.’s initial public offering. We are selling 7,500,000 shares of our common stock. Currently, no public market exists for the shares. Our common stock has been approved for listing on the Nasdaq Global Market under the symbol “DRTX

DURATA THERAPEUTICS, INC. 7,500,000 Shares Common Stock

Free Writing Prospectus Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated July 18, 2012 Relating to Preliminary Prospectus dated July 9, 2012 Registration No.

-

Acceleration Request Durata Therapeutics, Inc. 89 Headquarters Plaza North, 14th Floor Morristown, New Jersey 07960 July 16, 2012 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Durata Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-180280 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 46

- FORM 8-A

Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Durata Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1247903 (State of incorporation or organization) (I.R.S. Employer Identification No.) 89 Head

DURATA THERAPEUTICS, INC. (a Delaware corporation) [—] Shares of Common Stock UNDERWRITING AGREEMENT

Underwriting Agreement Exhibit 1.1 DURATA THERAPEUTICS, INC. (a Delaware corporation) [—] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [—], 2012 DURATA THERAPEUTICS, INC. (a Delaware corporation) [—] Shares of Common Stock UNDERWRITING AGREEMENT [—], 2012 Merrill Lynch, Pierce, Fenner & Smith Incorporated Credit Suisse Securities (USA) LLC as Representatives of the several Underwriters c/o

CERTIFICATE OF AMENDMENT THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION DURATA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DURATA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Durata Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: A

- AMENDMENT NO. 4 TO FORM S-1

Table of Contents As filed with the Securities and Exchange Commission on July 9, 2012 Registration No.

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Supply Agreement Exhibit 10.17 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. SUPPLY AGREEMENT This SUPPLY AGREEMENT (this “Agreement”) entered into this 12 day of June 2012 (the “Effective Date”) by and between Gnosis Bioresearch srl., a subsidiary fully owned company by GNOSIS SPA organized under the laws of Italy whos

EMPLOYMENT AGREEMENT

Exhibit 10.14 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this 20th day of June, 2012 (the “Effective Date”), by and between Durata Therapeutics, Inc., a Delaware corporation (the “Company”), and John Shannon (the “Executive”). THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions: A. The Company desires t

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Employment Agreement - Corey N. Fishman Exhibit 10.12 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this 6th day of June, 2012 (the “Effective Date”), by and between Durata Therapeutics, Inc., a Delaware corporation (the “Company”), and Corey N. Fishman (the “Executive”) and amends and restates in its entirety t

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Employment Agreement - Michael W. Dunne Exhibit 10.13 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this 10th day of June, 2012 (the “Effective Date”), by and between Durata Therapeutics, Inc., a Delaware corporation (the “Company”), and Michael Dunne (the “Executive”) and amends and restates in its entirety the

LIST OF SUBSIDIARIES OF DURATA THERAPEUTICS, INC. Entity Jurisdiction of Incorporation or Organization Durata Therapeutics Holding C.V. The Netherlands Durata Therapeutics International B.V. The Netherlands Vicuron Pharmaceuticals Inc. Delaware

Subsidiaries of the Registrant EXHIBIT 21.1 LIST OF SUBSIDIARIES OF DURATA THERAPEUTICS, INC. Entity Jurisdiction of Incorporation or Organization Durata Therapeutics Holding C.V. The Netherlands Durata Therapeutics International B.V. The Netherlands Vicuron Pharmaceuticals Inc. Delaware

DURATA THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive Plan

Form of Incentive Stock Option Agreement Exhibit 10.4 DURATA THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Durata Therapeutics, Inc., a Delaware corporation (the “Company”), on , 2012 (the “Grant Date”) to [ ], an employee of the Company (the “Participant”), of an option to purchase, in whole or

- AMENDMENT NO.3 TO FORM S-1

Amendment No.3 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 22, 2012 Registration No. 333-180280 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DURATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 27-124

DURATA THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan

Form of Nonstatutory Stock Option Agreement Exhibit 10.5 DURATA THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Durata Therapeutics, Inc., a Delaware corporation (the “Company”), on , 2012 (the “Grant Date”) to [ ], an [employee], [consultant], [director] of the Company (the “Participant”), of

DURATA THERAPEUTICS, INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMP

Specimen Stock Certificate Exhibit 4.1 DURATA THERAPEUTICS, INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN R

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Stock Purchase Agreement Exhibit 10.8 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Execution Version STOCK PURCHASE AGREEMENT Dated as of December 11, 2009 between PFIZER, INC. and DURATA THERAPEUTICS, INC. TABLE OF CONTENTS Page 1. DEFINITIONS; CERTAIN RULES OF CONSTRUCTION 1 2. PURCHASE AND SALE OF SHARES 12 2.1. Pur

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Employment Agreement - Paul R. Edick Exhibit 10.11 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this 19th day of June 2012 (the “Effective Date”), by and between (i) Durata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (ii) Paul Edick (the “Executive”) and amends and restates in its entiret

AMENDMENT TO STOCK INCENTIVE PLAN DURATA THERAPEUTICS, INC.

Stock Incentive Plan, as amended Exhibit 10.1 AMENDMENT TO STOCK INCENTIVE PLAN OF DURATA THERAPEUTICS, INC. The Durata Therapeutics, Inc. Stock Incentive Plan (the “Plan”), pursuant to Sections 7.7.1 and 7.7.2 thereof, is hereby amended as follows: Section 4.2 of the Plan is hereby amended to insert 17,000,000 in lieu of 15,000,000. Except as set forth above, the remainder of the Plan shall remai

DURATA THERAPEUTICS, INC. Director Compensation and Reimbursement Policy

EX-10.16 4 d312438dex1016.htm DIRECTOR COMPENSATION POLICY Exhibit 10.16 DURATA THERAPEUTICS, INC. Director Compensation and Reimbursement Policy This Director Compensation and Reimbursement Policy of Durata Therapeutics, Inc. (the “Corporation”) provides for compensation of each member of the Board of Directors (the “Board”) of the Corporation who is not an employee of the Corporation or any subs

- AMENDMENT NO.2 TO FORM S-1

Table of Contents As filed with the Securities and Exchange Commission on May 18, 2012 Registration No.

INDEMNIFICATION AGREEMENT

Form of Indemnification Agreement for Directors and Officers Exhibit 10.15 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Durata Therapeutics, Inc., a Delaware corporation (the “Company”), [ , a Delaware limited partnership (the “Fund”),]1 and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the

-

Response Letter Brian A. Johnson +1 212 937 7206(t) +1 212 230 8888(f) [email protected] May 18, 2012 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jeffrey P. Riedler Re: Durata Therapeutics, Inc. Registration Statement on Form S-1 File Number 333-180280 Ladies and Gentlemen: On behalf of Durata T

-

SEC Response Letter April 30, 2012 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jeffrey P.

DURATA THERAPEUTICS, INC. STOCK INCENTIVE PLAN STOCK OPTION AGREEMENT

Exhibit 10.2 DURATA THERAPEUTICS, INC. STOCK INCENTIVE PLAN STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this “Option Agreement”) dated XX by and between Durata Therapeutics, Inc., a Delaware corporation (the “Corporation”), and XX (the “Participant”) evidences the stock option (the “Option”) granted by the Corporation to the Participant as to the number of shares of the Corporation’s Commo

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Stock Purchase Agreement Exhibit 10.8 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Execution Version STOCK PURCHASE AGREEMENT Dated as of December 11, 2009 between PFIZER, INC. and DURATA THERAPEUTICS, INC. TABLE OF CONTENTS Page 1. DEFINITIONS; CERTAIN RULES OF CONSTRUCTION 1 2. PURCHASE AND SALE OF SHARES 12 2.1. Pur

DURATA THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive Plan

Form of Incentive Stock Option Agreement Exhibit 10.4 DURATA THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Durata Therapeutics, Inc., a Delaware corporation (the “Company”), on , 2012 (the “Grant Date”) to [ ], an employee of the Company (the “Participant”), of an option to purchase, in whole or

DURATA THERAPEUTICS, INC. 2012 Stock Incentive Plan

2012 Stock Incentive Plan Exhibit 10.3 DURATA THERAPEUTICS, INC. 2012 Stock Incentive Plan 1. Purpose The purpose of this 2012 Stock Incentive Plan (the “Plan”) of Durata Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important c

- AMENDMENT NO.1 TO FORM S-1

Amendment No.1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on April 30, 2012 Registration No. 333-180280 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DURATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 27-12

RESTATED CERTIFICATE OF INCORPORATION DURATA THERAPEUTICS, INC. (originally incorporated on November 4, 2009)

Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF DURATA THERAPEUTICS, INC. (originally incorporated on November 4, 2009) Durata Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: A. The current name of the Corporation is Durata Therapeutics, I

DURATA THERAPEUTICS, INC. Power of Attorney

Power of Attorney for Richard U. De Schutter Exhibit 24.2 DURATA THERAPEUTICS, INC. Power of Attorney The person whose signature appears below appoints Paul R. Edick and Corey Fishman, and each of them singly (with full power to each of them to act alone), his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, p

DURATA THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan

Form of Nonstatutory Stock Option Agreement Exhibit 10.5 DURATA THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Durata Therapeutics, Inc., a Delaware corporation (the “Company”), on , 2012 (the “Grant Date”) to [ ], an [employee], [consultant], [director] of the Company (the “Participant”), of

DURATA THERAPEUTICS, INC. Power of Attorney

Exhibit 24.3 DURATA THERAPEUTICS, INC. Power of Attorney The person whose signature appears below appoints Paul R. Edick and Corey Fishman, and each of them singly (with full power to each of them to act alone), his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities

AMENDED AND RESTATED BYLAWS DURATA THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 3 1.8 Vot

Amended and Restated By-laws of the Registrant Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF DURATA THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 3 1.8 Voting and Proxies 3 1.9 Action at Meeting 3 1.10 Nomination of Directors 4 1.11 Notice of

DURATA THERAPEUTICS, INC. STOCK INCENTIVE PLAN

Stock Incentive Plan Exhibit 10.1 DURATA THERAPEUTICS, INC. STOCK INCENTIVE PLAN PREFACE This Plan is divided into two separate equity programs: (1) the option and stock appreciation rights grant program set forth in Section 5 under which Eligible Persons (as defined in Section 3) may, at the discretion of the Administrator, be granted Options and/or SARs, and (2) the stock award program set forth

LIST OF SUBSIDIARIES OF DURATA THERAPEUTICS, INC. Entity State of Incorporation or Organization Vicuron Pharmaceuticals Inc. Delaware

Subsidiaries of the Registrant EXHIBIT 21.1 LIST OF SUBSIDIARIES OF DURATA THERAPEUTICS, INC. Entity State of Incorporation or Organization Vicuron Pharmaceuticals Inc. Delaware

DURATA THERAPEUTICS, INC. STOCK INCENTIVE PLAN FORM OF STOCK OPTION AGREEMENT

Form of Stock Option Agreement under the Stock Incentive Plan Exhibit 10.2 DURATA THERAPEUTICS, INC. STOCK INCENTIVE PLAN FORM OF STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this “Option Agreement”) dated by and between Durata Therapeutics, Inc., a Delaware corporation (the “Corporation”), and (the “Participant”) evidences the stock option (the “Option”) granted by the Corporation to the P

OFFICE SERVICES AGREEMENT Date of Agreement: December 24, 2010 Agreement No. 079-1436-11 Provider (also referred to in this Agreement as “We”, “Us” or “Our”): Chartwell Consulting Group, Inc. t/a Symphony Suites Client (also referred to in this Agree

Office Services Agreement Exhibit 10.7 OFFICE SERVICES AGREEMENT Date of Agreement: December 24, 2010 Agreement No. 079-1436-11 Provider (also referred to in this Agreement as “We”, “Us” or “Our”): Chartwell Consulting Group, Inc. t/a Symphony Suites Client (also referred to in this Agreement as “You” or “Your”): Durata Therapeutics, Inc. 89 Headquarters Plaza North Tower, 14th Floor Morristown, N

DEVELOPMENT AND SUPPLY AGREEMENT

Development and Supply Agreement Confidential Materials omitted and filed separately with the Securities and Exchange Commission.

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Rights Transfer Agreement Confidential Materials omitted and filed separately with the Securities and Exchange Commission.

Registration Statement - FORM S-1

Form S-1 Table of Contents As filed with the Securities and Exchange Commission on March 22, 2012 Registration No.

BYLAWS DURATA THERAPEUTICS, INC. a Delaware corporation ARTICLE I.

By-laws of the Registrant Exhibit 3.2 BYLAWS OF DURATA THERAPEUTICS, INC. a Delaware corporation ARTICLE I. OFFICES Section 1. Registered Office. The registered office of Durata Therapeutics, Inc. (the “Corporation”) shall be at the office of the The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, State of Delaware. Section

INVESTOR RIGHTS AGREEMENT By and Among DURATA THERAPEUTICS, INC. THE HOLDERS OF PREFERRED SHARES THEREOF TABLE OF CONTENTS Page 1. DEFINITIONS; RULES OF CONSTRUCTION 1 (a) Definitions 1 (b) Rules of Construction 3 2. REGISTRATION RIGHTS 4 (a) Demand

Investor Rights Agreement,dated December 11, 2009 Exhibit 10.6 INVESTOR RIGHTS AGREEMENT By and Among DURATA THERAPEUTICS, INC. and THE HOLDERS OF PREFERRED SHARES THEREOF TABLE OF CONTENTS Page 1. DEFINITIONS; RULES OF CONSTRUCTION 1 (a) Definitions 1 (b) Rules of Construction 3 2. REGISTRATION RIGHTS 4 (a) Demand Registration 4 (b) Designation of Joint Counsel 6 3. PIGGYBACK REGISTRATIONS 6 (a)

State of Delaware Secretary of State Division of Corporations Delivered 07:36 PM 12/01/2010 FILED 07:29 PM 12/01/2010 SRV 101139403 – 4722139 FILE

Certificate of Incorporation of the Registrant, as amended Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 07:36 PM 12/01/2010 FILED 07:29 PM 12/01/2010 SRV 101139403 – 4722139 FILE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DURATA THERAPEUTICS, INC. (Pursuant to Sections 103, 242 and 245 of the General Corporation Law of the State of Delaware) D